TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Muscular Dystrophy Association
FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease

The FDA approved Amgen's UPLIZNA® (inebilizumab-cdon) as the first CD19-Targeted B-Cell therapy for generalized myasthenia gravis, offering patients a new treatment option with potential long-term disease control using just two doses annually.

Insights
AMGN   positive

Received FDA approval for a novel therapeutic treatment, expanding their product portfolio and addressing an unmet medical need in neuromuscular disease management